Abstract
Hypertrophic cardiomyopathy (HCM) is associated with increased left ventricular (LV) mass, decreased myocardial strain, and the presence of LV fibrosis and scar. The relationship between LV scar and fibrosis with left atrial (LA) fibrosis in the setting of HCM has not been examined. The purpose of this study is to demonstrate a correlation between the degree of LA fibrosis and LV parameters in subjects with HCM. Twenty-eight subjects with HCM were imaged on a 1.5T MRI scanner with cine, LV and LA late gadolinium enhancement (LGE) sequences. LA LGE and LA measurements were correlated with LV measurements of volumes, mass, strain, and LGE. Other clinical conditions and medication usage were also examined and evaluated for correlation with LA and LV parameters. LV LGE was identified in 24 (86%) of the cases and LA LGE was identified in all of the cases. Extent of LA fibrosis significantly correlated with percent LV LGE (r = 0.64, p = 0.001), but not with indexed LV mass or maximum wall thickness. Extent of LA fibrosis also moderately correlated with decreased LV global strain (radial, r = − 0.50, p = 0.013; circumferential, r = 0.47, p = 0.02; longitudinal, r = 0.52, p = 0.013). Increased LA systolic volume correlated moderately with LV end diastolic volume (r = 0.50, p = 0.006). Patients on therapy with Renin-Angiotensin-Aldosterone System (RAAS) Inhibition had significantly less LA LGE compared to those without (18.6% vs 10.8%, p = 0.023). LA fibrosis, as measured by LGE, is prevalent in HCM and is correlated with LV LGE. The correlation between LA and LV LGE might suggest either that LA fibrosis is a consequence of LV remodeling, or that LA and LV fibrosis are both manifestations of the same cardiomyopathic process. Further study is warranted to determine the causality of LA scar in this population.
Similar content being viewed by others
Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on request.
Abbreviations
- ACE-I:
-
Ace inhibitors
- AF:
-
Atrial fibrillation
- ARB:
-
Angiotensin receptor blockers
- CMR:
-
Cardiovascular magnetic resonance
- ECG:
-
Electrocardiogram
- EF:
-
Ejection fraction
- GRAPPA:
-
Generalized auto calibrating partially parallel acquisition
- HCM:
-
Hypertrophic cardiomyopathy
- LA:
-
Left atrium/atrial
- LGE:
-
Late gadolinium enhancement
- LIFE:
-
Losartan intervention for end point reduction in hypertension study
- LV:
-
Left ventricle/ventricular
- mm:
-
Millimeter
- mm3 :
-
Millimeter cubed
- mmol/kg:
-
Millimole/kilogram
- PACS:
-
Picture archiving and communication system
- RAAS:
-
Renin–Angiotensin–Aldosterone system
- SCD:
-
Sudden cardiac death
- SSFP:
-
Steady state free precession
- STE:
-
Speckle tracking echocardiography
- TDI:
-
Tissue Doppler imaging
- TE:
-
Echo time
- TR:
-
Repetition time
References
Quarta G, Grasso A, Pasquale F et al (2011) Evaluation and clinical importance of fibrosis in HCM. J Am Coll Cardiol Imaging 4:1221–1223
Maron BJ, Bonow RO, Salberg L et al (2008) The first patient clinically diagnosed with hypertrophic cardiomyopathy. Am J Cardiol 102:1418–1420
Syed IS, Ommen SR, Breen JF et al (2008) Hypertrophic cardiomyopathy: identification of morphological subtypes by echocardiography and cardiac magnetic resonance imaging. J Am Coll Cardiol Imaging 1:377–379
Moravsky G, Ofek E, Rakowski H et al (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. J Am Coll Cardiol Imaging 6:597–599
Reichek N, Gupta D (2008) Hypertrophic cardiomyopathy: cardiac magnetic resonance imaging changes the paradigm. J Am Coll Cardiol 52:567–568
Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. J Am Coll Cardiol Imaging 9:1392–1402
Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:875–887
Smiseth OA, Torp H, Opdahl A et al (2016) Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J 37:1196–1207
Popovic ZB, Kwon DH, Mishra M et al (2008) Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyper-enhancement magnetic resonance imaging. J Am Soc Echocardiogr 21:1299–1305
Saito M, Okayama H, Yoshii T et al (2012) Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Eur Heart J 13:617–623
Macron L, Redheuil A, Ashrafpoor G et al (2013) Global circumferential left ventricular strain impairment in hypertrophic cardiomyopathy: comparison to left ventricular hypertrophy and late gadolinium enhancement. J Cardiovasc Magn Reson 15(Suppl 1):E122
Losi MA, Betocchi S, Barbati G et al (2009) Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 22:76–81
Yang H, Woo A, Monakier D et al (2005) Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr 18:1074–1082
Olivotto I, Cecchi F, Casey SA et al. (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104(21):2517–2524
Hauser TH, Peters DC, Wylie JV et al (2008) Evaluating the left atrium by magnetic resonance imaging. Europace 10:iii22–iii27
Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr 28:1–39
Cao JJ, Ngai N, Duncanson L et al (2018) A comparison of both DENSE and feature tracking techniques with tagging for the cardiovascular magnetic resonance assessment of myocardial strain. J Cardiovasc Magn Reson 20(1):26
Pedrizzetti G, Claus P, Kilner PJ et al (2016) Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J Cardiovasc Magn Reson 18:51
Karim R, Housden R, Balasubramaniam M et al (2013) Evaluation of current algorithms for segmentation of scar tissue from late Gadolinium enhancement cardiovascular magnetic resonance of the left atrium: an open-access grand challenge. J Cardiovasc Magn Reson 15(1):105
Nakamura K, Funabashi N, Uehara M et al (2011) Left atrial wall thickness in paroxysmal atrial fibrillation by multislice-CT is initial marker of structural remodeling and predictor of transition from paroxysmal to chronic form. Int J Cardiol 148:139–147
Kikinis R, Pieper SD, Vosburgh KG (2014) 3D Slicer: a platform for subject-specific image analysis, visualization, and clinical support. In Intraoperative imaging and image-guided therapy (pp. 277–289). Springer, New York
Quail M, Grunseich K, Baldassarre LA, Mojibian H, Marieb MA, Cornfeld D, Soufer A, Sinusas AJ, Peters DC (2019) Prognostic and functional implications of left atrial late gadolinium enhancement. J Cardiovasc Magn Reson 21:2
Cochet H, Mouries A, Nivet H et al (2015) Age, atrial fibrillation, and structural heart disease are the main determinants of left atrial fibrosis detected by delayed-enhanced magnetic resonance imaging in a general cardiology population. J Cardiovasc Electrophysiol 26:484–492
Marrouche NF, Wilber D, Hindricks G et al (2014) Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311(5):498–506
Wylie JV, Peters DC, Essebag V et al (2008) Left atrial function and scar after catheter ablation of atrial fibrillation. Heart Rhythm 5(5):656–662
Chan RC, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495
Kowallick JT, Vieira MS, Kutty S et al (2017) Left atrial performance in the course of hypertrophic cardiomyopathy: relation to left ventricular hypertrophy and fibrosis. Invest Radiol 52(3):177–185
Debonnaire P, Joyce E, Hiemestra Y et al (2017) LA size and function versus AF risk in HCM. Circ Arrhythm Electrophys 10:1–10
Farhad H et al (2017) Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson 19(1):107
Xiao HD et al (2004) Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165(3):1019–1032
Nakajima H, Nakajima HO, Salcher O et al (2000) Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta (1) transgene in the heart. Circ Res 86:571–579
Verheule S, Sato T, Everett T et al (2004) Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94:1458–1465
Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L (1991) Collagen expression in mechanically stimulated cardiac fibroblasts. Circ Res 69:116–122
Peters DC, Duncan JS, Grunseich K et al (2017) CMR-verified lower LA strain in the presence of regional atrial fibrosis in atrial fibrillation. J Am Coll Cardiol Imaging 10:207–208
Lombardi R, Betocchi S, Losi MA et al (2003) Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 108(12):1455–1460
Haland TF et al (2016) Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. Eur Heart J 17(6):613–621
Savelieva I, Kakouros N, Kourliouros A et al (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13(3):308–328
Wachtell K, Lehto M, Gerdts E et al (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45(5):712–719
Maggioni AP, Latini R, Carson PE et al (2005) Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (Val-HeFT). Am Heart J 149(3):548–557
Author information
Authors and Affiliations
Contributions
SRL, VQN, MLH, KG, DCP, LAB collected imaging data, performed chart review, and performed literature review. SRL, VQN, DCP, and LAB analyzed the CMR studies. LAB, SRL, and DCP conceived of the study, and participated in its design and coordination. SRL, MLH, KG, VQN, DCP, JT, DJH, SH, HM, DD, AJS, JLM, NP, DJ, LAB participated in analysis and interpretation of the patient data and contributed to writing the manuscript. AS and DCP performed intra- and interobserver variability. SRL, VQN, MLH, DCP, and LAB were major contributors in writing the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval
This study was approved by the Yale IRBS—Yale University Institutional Review Board, specifically the Human Investigation Committee, and is HIPAA compliant.
Informed consent
No informed consent was required since this is a retrospective data review.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Latif, S.R., Nguyen, V.Q., Peters, D.C. et al. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 35, 1309–1318 (2019). https://doi.org/10.1007/s10554-019-01551-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10554-019-01551-7